The nurse is assessing the neurovascular status of a 10-year-old child in Russell traction. Which of the following findings should be reported immediately?

Neurovascular compromise in orthopedic traction results from impaired arterial perfusion, venous return obstruction, compartment pressure elevation, and nerve compression. Early detection is critical to prevent ischemia, tissue necrosis, and permanent neuromuscular damage, especially in pediatric patients with smaller vascular and soft tissue compartments.

Rationale:

A. Cool, pale skin indicates arterial insufficiency and reduced peripheral tissue perfusion, suggesting acute neurovascular compromise. This may precede irreversible ischemia and requires immediate intervention to prevent compartment syndrome and potential loss of limb viability.

B. Slight edema reflects expected post-traumatic inflammatory response and mild venous congestion in immobilized limbs. While it requires monitoring, it does not indicate immediate vascular compromise or neurologic deterioration requiring emergent action.

C. Yellow-green bruising represents normal hemoglobin breakdown during the healing process. This color change occurs in resolving hematoma stages and indicates tissue recovery rather than active neurovascular impairment or circulatory compromise.

D. A pedal pulse of 82/min is within normal pediatric limits and indicates preserved distal arterial flow. Presence of an adequate pulse suggests that major vascular compromise is not occurring at the time of assessment.

The infant immunologic response requires sequential antigen exposure to stimulate optimal antibody titers against virulent pathogens. The primary series prevents bordetella pertussis colonisation and neutralizes clostridium tetani exotoxins by establishing long-term memory B-lymphocyte populations.

Rationale:

DTaP is a combination vaccine administered at 2, 4, and 6 months of age to provide critical immunity against diphtheria, tetanus, and acellular pertussis. This precise schedule ensures optimal active immunity during peak developmental vulnerability periods.

HepB is typically initiated at birth, with subsequent doses administered at 2 and 6 months of age. While it is given 3 times within the first 6 months, the birth dose alters the 2, 4, 6-month sequence typical of other primary infant series.

Hib conjugate vaccines protect against invasive Haemophilus influenzae type b diseases like meningitis. Depending on the specific manufacturer formulation used, the primary series may require either 2 or 3 doses before the 6-month milestone.

PCV13 or PCV15 protects against invasive pneumococcal diseases. It requires 3 doses at 2, 4, and 6 months, followed by a 4th booster dose at 12 to 15 months of age.